Healthy Extracts Reports Results for Third Quarter and Nine Months 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Healthy Extracts (HYEX) reported third-quarter revenue of $619,000, down year over year as a promotional credit and inventory constraints limited sales. The approximately $300,000 credit went to a new pharmacy retailer customer. Quarterly gross margin rose to 54.7% from 48.7%, but net loss widened to $1,712,979 from $395,394.
For the nine months ended September 30, 2026, revenue rose 53% to a record $4.3 million, largely reflecting the Gummy USA merger and Imaraïs Beauty acquisition. Gross profit increased 90% to $2.8 million, while net loss widened to $1,931,870 from $727,133. Cash was $143,000 versus $147,000 at year-end 2025. The company expects sequential revenue growth to resume in the fourth quarter and full-year revenue to reach a record. Its aspirational annualized net revenue run-rate target of more than 3x last year remains dependent on market forces and customer timing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNine-month revenue rose 53% to a record $4.3 million, from $2.8 million a year earlier.
- Moderate pointNine-month gross profit increased 90% to $2.8 million, from $1.5 million a year earlier.
- Moderate pointNine-month gross margin improved to 64.7% from 52.0% a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter sequential revenue growth is expected to resume, producing record full-year net revenue.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Annualized net revenue run rate has an aspirational target of more than 3x last year.
5 minor points
- Minor pointQuarterly gross margin improved to 54.7% from 48.7% a year earlier.
- Minor pointGummy USA and Imaraïs Beauty acquisitions added product lines, B2B customers and distribution channels.
- Minor pointGummy USA received FDA approval and certification in April 2026 enabling controlled substances in future oral delivery products.
- Minor pointHealthy Extracts reported a customer win with a Canadian pharmacy chain.
- Minor pointImaraïs Beauty expansion preparations included approximately $200,000 in inventory buildup and increased manufacturing shifts.
Negative
- Moderate pointQuarterly revenue declined 33% to $619,000, from $918,000 a year earlier.
- Moderate pointQuarterly gross profit declined 24% to $339,000, from $447,000 a year earlier.
- Moderate pointQuarterly net loss widened to $1,712,979 from $395,394; loss per share increased to $0.12 from $0.06.
- Moderate pointQuarterly operating expenses increased to $1.6 million from $907,000 a year earlier.
- Moderate pointQuarterly adjusted EBITDA loss widened to $843,000 from $52,000; per-share loss rose to $0.06 from $0.01.
7 minor points
- Minor pointA one-time pharmacy retailer promotional credit reduced quarterly revenue by approximately $300,000.
- Minor pointTemporary inventory constraints limited planned third-quarter customer shipments.
- Minor pointNine-month net loss widened to $1,931,870 from $727,133; loss per share increased to $0.12 from $0.11.
- Minor pointNine-month operating expenses increased to $4.4 million from $2.1 million a year earlier.
- Minor pointNine-month adjusted EBITDA loss widened to $478,000 from $146,000; per-share loss rose to $0.03 from $0.02.
- Minor pointCash declined to $143,000 at September 30, 2026, from $147,000 at December 31, 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.The aspirational revenue run-rate target depends on market forces and customer timing outside company control.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAS VEGAS, NV / ACCESS Newswire / November 16, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical formulations and precision dose gummy manufacturing, reported results for the third quarter and nine months ended September 30, 2026. Financial comparisons are to the same year-ago period unless otherwise noted.
Financial Highlights
- Net revenue for the third quarter totaled
$619,000 , declining33% , with nine months revenue up53% to a record$4.3 million . Third quarter 2026 revenue was reduced by a one-time promotional credit to new major pharmacy retailer customer of approximately$300,000 , as well by temporary inventory constraints that limited planned customer shipments. Sequential quarterly growth is expected to return in the current fourth quarter, resulting in record revenues for the year. - Strong nine-month topline performance largely due to synergistic merger with Gummy USA™ in October 2025 and acquisition of Imaraïs Beauty in May of this year. Both added new product lines and B2B customers and expanded the company's distribution channels.
- Gross profit in the third quarter totaled
$339,000 , down24% , with nine months gross profit up90% to$2.8 million . - Gross margin in the third quarter improved from
48.7% to54.7% , with nine month's gross margin improving from52.0% to64.7% . - Net loss totaled
$1.7 million or$(0.12) per basic and diluted share in the third quarter, compared to net loss of$395,000 or$(0.06) per basic and diluted share in the same year-ago quarter. Net loss for the nine months totaled$1.9 million or$(0.12) per basic and diluted share, compared to net loss of$727,000 or$(0.11) per basic and diluted share in the same year-ago period. The increases in net loss were largely due to increased interest expense, change in fair value of derivatives, and increased G&A expense related to the addition of Gummy USA and Imaraïs Beauty. This includes the buildup of approximately$200,000 in inventories in preparation for Imaraïs Beauty's accelerating U.S. and international expansion as well as the associated increase in manufacturing shifts.
Q3 2026 Operational Highlights
- Imaraïs Beauty products for health, wellness and beauty launched at an additional 4,000 pharmacy retail locations nationwide. The products' stylistic packaging has received prominent store shelf positioning on end-cap displays and are easy to find in the retailer's online store. The products include Imaraïs Beauty's most popular functional beauty and wellness gummies for skincare, haircare, gut health and overall wellness. The proprietary, clinically backed ‘ingestible beauty' formulations offer valuable health benefits and a unique consumer experience.
- Continued focus on Imaraïs Beauty's broad distribution across major U.S. and international retail channels, including Target, Ulta Beauty, Nordstrom and Sprouts, as well as numerous international outlets. Leveraging Imaraïs Beauty's phenomenal success that has been featured in major business publications, including WWD, Forbes, Beauty Independent and Entrepreneur.
- Healthy Extracts' transformative strategic merger with Gummy USA in October 2025 continued to address the large unmet need in the nutraceutical and pharmaceutical industry for precision-dosed gummy manufacturing technology, opening the door to new specialized B2B product development. This includes leveraging the FDA approval and certification received in April 2026 that enables Gummy USA to include controlled substances, like nicotine for smoking cessation, in future oral delivery products it may manufacture. The company believes this certification is unique to Gummy USA, providing a competitive edge.
Management Commentary
"Our third quarter of 2026 represented another milestone period of new business development and market expansion as we continue to transform Healthy Extracts into a global provider of precision dosed gummies and other oral delivery systems," stated Healthy Extracts CEO, Don Swanson.
"Our strong topline performance for the nine-month period reflects the continued evolution of our company into an industry leader in nutraceutical innovation. The integrations of Gummy USA and Imarais Beauty have provided a new foundation for accelerated growth, driven by expanded product lines and the broadening of our addressable markets. They have also introduced new major retailer customers in the U.S. and from around the world, resulting in significant B2B sales.
"While temporary inventory constrains limited our sales in the third quarter, we have continued to focus on our long-term strategic growth strategies. This includes achieving superior leadership in formulation and manufacturing technologies that target the high-growth, high-margin Nutra Pharma and Health & Beauty sectors. We expect these efforts to benefit from strong growth in the health and beauty sector which is expected to top
"Our acquisition of Imaraïs Beauty has also continued to deliver strong synergies with our Gummy USA operations. Their advanced formulations are unlike anything in the market today, and our precision dosing technology aligns perfectly with their long-standing dedication to premium quality, best-in-class innovation, and rapid global expansion.
"As we move through the final months of 2026 and prepare for the new year, we continue to expect Imaraïs' market reach and retail momentum to accelerate our in-house gummy manufacturing output.
"We believe we are at the beginning of a highly scalable, transformational growth phase for the entire company. By leveraging our advanced U.S. manufacturing capabilities, we see tremendous opportunities to expand our brand presence worldwide. This was demonstrated with the recent big win in Canada of one of the nation's largest and longest-established pharmacy chains. We hope to soon release additional information on this major win.
"Given our many ongoing commercial initiatives, including new B2B customer engagements and product development, we still believe we have the potential to achieve an annualized net revenue run rate of more than 3x over last year. While this aspirational goal is aggressive, and dependent on market forces and certain customer timings outside of our control, we believe it is well supported by our sales pipeline and manufacturing and distribution capacity.
"We see our Gummy USA and Imaraïs Beauty merger deals reflecting a period of strengthening investor interest and consolidation within the gummy and wellness sector. Many other high-profile transactions, such as the
"As we turn our sights on 2027, our mission remains clear: build one of the most trusted, innovative, and respected health, wellness and beauty companies in the world, and this delivering sustainable long-term value to our stakeholders. Thank you for joining us on this exciting journey and we appreciate your support as we work through the many high-reward challenges ahead."
Q3 and 9M 2026 Financial Summary
Net revenue declined
Third quarter 2026 net revenue was reduced by a one-time promotional credit to a new major pharmacy retailer customer totaling approximately
The increase in the first nine months of 2026 was largely due to the synergistic merger the company completed with Gummy USA™ in October 2025 and the acquisition of Imaraïs Beauty in May of this year. These acquisitions added new product lines and B2B customers as well as expanded the company's distribution channels. The company expects its net revenue growth to improve over the coming quarters as its direct consumer sales and marketing efforts continue to perform.
Gross profit in the third quarter of 2026 declined
Gross margin improved from
Operating expenses were
Net loss for the third quarter totaled
The company's net income or loss varies from period to period primarily due to the change in fair value on derivative and increases in general and administrative expenses. The increase in net loss in the third quarter and first nine months of 2026 was largely due to increased interest expense, change in the fair value of derivatives, and increased G&A expense related to the addition of Gummy USA and Imaraïs Beauty. This includes the buildup of approximately
Adjusted EBITDA, which adjusts additionally for non-cash stock-based expense and change in fair value of derivatives, totaled a loss of
Adjusted EBITDA in the first nine months totaled a loss of
Cash totaled
About Healthy Extracts "Live Life Young Again"
Healthy Extracts Inc. (OTCQB:HYEX) is a leader in nutraceutical innovation, precision-dose oral delivery systems, and functional wellness consumer brands. The company develops, manufactures, and markets science-based products focused on beauty, wellness, brain, heart, gut, and lifestyle health through proprietary formulations, advanced delivery technologies, and scalable national retail distribution.
Through its acquisition of Imaraïs Beauty, the celebrity-founded ingestible beauty and wellness brand co-founded by Sommer Ray and entrepreneur Aaron Hefter, Healthy Extracts has significantly expanded its position within the rapidly growing global beauty and personal care market. Imaraïs Beauty combines advanced functional beauty formulations with strong consumer engagement, influencer-driven branding, and expanding global retail distribution across major U.S. retailers, including Target, CVS, Ulta Beauty, Nordstrom and Sprouts, and retailers in international markets.
Healthy Extracts' wholly owned subsidiary, Gummy USA™, is a leading developer and manufacturer of precision-dosed nutraceutical and pharmaceutical-grade gummies. Proprietary, patent-pending SureDose™ technology is designed to deliver superior dosing accuracy, safety, efficacy, and consumer compliance for both company-owned and partner brands.
The company's portfolio also includes BergametNA™ and Ultimate Brain Nutrients™ (UBN™) which offer science-backed supplements supporting cardiovascular and cognitive health. Healthy Extracts additionally maintains exclusive agreements for innovative oral delivery technologies, including Gelteq gel delivery systems and the Gut Health Straw platform, which are designed to improve bioavailability and consumer convenience.
To learn more, visit Healthy Extracts Inc., Imaraïs Beauty, BergametNA, Ultimate Brain Nutrients, or Gummy USA.
Use of Non-GAAP Measures
This press release contains financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which may include EBITDA, adjusted EBITDA and non-GAAP net income as defined below for the purpose of this press release.
EBITDA is defined as net income before income tax expense, interest expense (net of interest income), depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding the gain or loss related to stock-based option/warrant expense, stock issued for services, change in fair value of derivative, offering costs, and M&A-related expense. Non-GAAP net income excludes interest expense (net of interest income), depreciation, amortization and stock-based expenses (stock-based option/warrant expense and stock issued for services), and M&A-related expense.
Healthy Extracts' management believes that EBITDA, adjusted EBITDA, and non-GAAP net income are useful supplemental measures of the company's operating performance and can provide investors meaningful measures of overall corporate performance. EBITDA is also presented because management believes that it is frequently used by investment analysts, investors, and other interested parties as a measure of financial performance. Adjusted EBITDA and non-GAAP net income are also presented because management believes that it provides investors additional measures of the company's core business. However, such non-GAAP measures do not have a standardized meaning prescribed by GAAP, and investors are cautioned that such non-GAAP measures should not be construed as an alternative to net income or loss or other income statement data (which are determined in accordance with GAAP) as an indicator of our performance or as a measure of liquidity and cash flows. Management's method of calculating EBITDA, adjusted EBITDA, and non-GAAP net income may differ materially from the method used by other companies and accordingly may not be comparable to similarly titled measures used by other companies.
A reconciliation of EBITDA and adjusted EBITDA to net income, the most comparable GAAP measure, is included in the table below. The calculation of non-GAAP net income is derived from the amounts presented in this table. For the weighted average number of common shares used for the determination of adjusted EBITDA and non-GAAP income basic and diluted earnings per common share, see the table, Consolidated Statement of Operations, further below.
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Net Income | $ | (1,712,979 | ) | $ | (395,394 | ) | $ | (1,931,870 | ) | $ | (727,133 | ) | ||||
Income tax expense | - | - | - | - | ||||||||||||
Interest expense, net of interest income | 131,600 | 56,171 | 323,128 | 119,988 | ||||||||||||
Depreciation and amortization | 156,168 | 635 | 504,261 | 1,329 | ||||||||||||
EBITDA | (1,425,211 | ) | (338,588 | ) | (1,104,481 | ) | (605,816 | ) | ||||||||
Stock-based option/warrant expense | 94,636 | 239,594 | 337,025 | 359,746 | ||||||||||||
Stock issued for services | 274,039 | 145,168 | 312,863 | 145,168 | ||||||||||||
Change in fair value of derivative | 212,462 | (120,891 | ) | (91,596 | ) | (67,423 | ) | |||||||||
One-Time Costs - Acquisitions | 1,480 | 22,645 | 68,180 | 22,645 | ||||||||||||
EBITDA adjustments | 582,617 | 286,516 | 626,472 | 460,136 | ||||||||||||
Adjusted EBITDA | $ | (842,595 | ) | $ | (52,071 | ) | $ | (478,009 | ) | $ | (145,680 | ) | ||||
Adjusted EBITDA per common share - basic and diluted | $ | (0.06 | ) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
Safe Harbor Notice and Important Cautions Regarding Forward-Looking Statements
The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its full second quarter results and files it Form 10-Q with the U.S. Securities and Exchange Commission (SEC).
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 8, 2026, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only to the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food & Drug Administration Disclosure
The products and formulations featured in this release are not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
Gummy USA ™, BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are trademarks and registered trademarks of Healthy Extracts™ Inc.
Company Contact
Don Swanson, CEO
Healthy Extracts Inc.
Tel (801) 232-0753
Email contact
Investor Contact
CMA Investor Relations
Tel (949) 432-7554
Email contact
HEALTHY EXTRACTS INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDING SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)
| FOR THE THREE MONTHS ENDING | FOR THE NINE MONTHS ENDING | |||||||||||||||
| SEPTEMBER 30, | SEPTEMBER 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
REVENUE | ||||||||||||||||
Revenue | $ | 619,326 | $ | 917,975 | $ | 4,296,668 | $ | 2,817,910 | ||||||||
Net revenue | 619,326 | 917,975 | 4,296,668 | 2,817,910 | ||||||||||||
COST OF REVENUE | ||||||||||||||||
Cost of goods sold | 280,521 | 470,725 | 1,517,128 | 1,352,848 | ||||||||||||
Total cost of revenue | 280,521 | 470,725 | 1,517,128 | 1,352,848 | ||||||||||||
GROSS PROFIT | 338,805 | 447,250 | 2,779,540 | 1,465,062 | ||||||||||||
OPERATING EXPENSES | ||||||||||||||||
General and administrative | 1,617,730 | 907,363 | 4,445,550 | 2,139,630 | ||||||||||||
Total operating expenses | 1,617,730 | 907,363 | 4,445,550 | 2,139,630 | ||||||||||||
OTHER INCOME (EXPENSE) | ||||||||||||||||
Interest expense, net of interest income | (131,600 | ) | (56,172 | ) | (323,128 | ) | (119,988 | ) | ||||||||
Change in fair value on derivative | (212,462 | ) | 120,891 | 91,596 | 67,423 | |||||||||||
Gain/loss of foreign transactions | (89,993 | ) | - | 35,672 | - | |||||||||||
Gain/loss of disposal of assets | - | - | (70,000 | ) | - | |||||||||||
Total other income (expense) | (434,055 | ) | 64,720 | (265,860 | ) | (52,565 | ) | |||||||||
Net income/(loss) before income tax provision | (1,712,979 | ) | (395,394 | ) | (1,931,870 | ) | (727,133 | ) | ||||||||
NET INCOME/(LOSS) | $ | (1,712,979 | ) | $ | (395,394 | ) | $ | (1,931,870 | ) | $ | (727,133 | ) | ||||
Income/(Loss) per share - basic and diluted | $ | (0.12 | ) | $ | (0.06 | ) | $ | (0.12 | ) | $ | (0.11 | ) | ||||
Weighted average number of shares outstanding - basic and diluted | 14,876,861 | 6,755,492 | 15,849,599 | 6,755,492 | ||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
HEALTHY EXTRACTS INC.
CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2026 AND DECEMBER 31, 2025
(UNAUDITED)
| SEPTEMBER 30, | DECEMBER 31, | |||||||
| 2026 | 2025 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash | $ | 143,267 | $ | 146,935 | ||||
Accounts receivable | 424,270 | 187,750 | ||||||
Inventory, net | 572,404 | 843,357 | ||||||
Offering costs | 149,274 | 149,274 | ||||||
Total current assets | 1,289,216 | 1,327,317 | ||||||
Fixed assets | 3,728,822 | 4,233,083 | ||||||
Deposit | 38,500 | 99,767 | ||||||
Goodwill | 26,175,456 | 21,123,922 | ||||||
Patents/Trademarks | 526,647 | 526,647 | ||||||
Right of use asset, net - non-current | 377,000 | 513,929 | ||||||
Total other assets | 30,846,425 | 26,497,347 | ||||||
TOTAL ASSETS | 32,135,641 | 27,824,664 | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
LIABILITIES | ||||||||
Accounts payable | 752,068 | 108,496 | ||||||
Accrued interest payable | 5,523 | 5,118 | ||||||
Accrued interest payable - related party | 140,630 | 76,401 | ||||||
Accrued liabilities | 573,662 | 613,645 | ||||||
Contract liabilities | 75,200 | - | ||||||
Lease liabilities - current | 202,593 | 171,930 | ||||||
Notes payable - current | 805,723 | - | ||||||
Notes payable - related party - current | 6,379,724 | 676,250 | ||||||
Convertible debt, net of discount - current | 230,625 | 111,330 | ||||||
Total current liabilities | 9,165,747 | 1,763,169 | ||||||
Lease liabilities - long-term | 176,903 | 344,265 | ||||||
Notes payable - non-current | 1,225,860 | 1,171,670 | ||||||
Notes payable - related party - non-current | 97,584 | 156,835 | ||||||
Convertible debt, net of discount - non-current | 6,750 | 6,750 | ||||||
Derivative liabilities | 260,815 | 352,411 | ||||||
Total non-current liabilities | 1,767,911 | 2,031,930 | ||||||
Total current and total liabilities | 10,933,658 | 3,795,099 | ||||||
STOCKHOLDERS' EQUITY | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 368,740 | 368,413 | ||||||
Additional paid-in capital | 46,779,110 | 43,788,013 | ||||||
Treasury stock, at cost, 2,163,686 shares, respectively | (3,892,536 | ) | (5,400 | ) | ||||
Accumulated deficit | (22,053,333 | ) | (20,121,462 | ) | ||||
Total stockholders' equity | 21,201,982 | 24,029,564 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 32,135,641 | $ | 27,824,664 | ||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
SOURCE: HEALTHY EXTRACTS INC.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Healthy Extracts HYEX revenue fall in the third quarter of 2026?
Third-quarter revenue fell 33% to $619,000, with sales reduced by an approximately $300,000 one-time promotional credit to a new pharmacy retailer customer and temporary inventory constraints that limited planned customer shipments.
What is Healthy Extracts HYEX revenue outlook after its third-quarter 2026 results?
Healthy Extracts expects sequential quarterly revenue growth to return in the fourth quarter, resulting in record full-year net revenue. Its separate annualized net revenue run-rate target of more than 3x last year is aspirational and depends on market forces and customer timing outside its control.
What drove Healthy Extracts HYEX higher net losses in 2026?
Healthy Extracts attributes the higher third-quarter and nine-month net losses largely to increased interest expense, changes in derivative fair value and higher general and administrative expenses related to adding Gummy USA and Imaraïs Beauty.